Q-omics provides the consensus-scored MIR1180 profile across patient tissues and cancer cell-line models. MIR1180 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MIR1180 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MIR1180 RNA expression shows 14,100 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, BRCA, and UVM as cancer lineages where MIR1180 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1180 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1180 survival associations across molecular data types. MIR1180 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1180 RNA expression–survival associations across cancer types. High MIR1180 expression shows unfavorable associations in CESC, UVM and LGG, but favorable associations in COAD, PAAD and MESO. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify COAD as the clearest survival context for MIR1180 RNA expression.
This table summarizes MIR1180 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1180. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1180 shows lower tumor expression in BRCA and UCEC and higher tumor expression in PAAD and LIHC. The BRCA box plot shows higher MIR1180 RNA expression in normal versus tumor tissue (log2 FC = −0.174, t-test p = .024).
This table shows molecular features associated with MIR1180 in patient tissues and cancer cell lines. In patient samples, MIR1180 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
